Medicare Weight Loss Drug Coverage 2026: Wegovy & Ozempic Rules

Roughly 74 million Americans are enrolled in Medicare — yet until July 2026, not one of them could get Wegovy or any GLP-1 weight-loss drug covered simply because of their weight.

That number stopped me cold when I first read it. I’m Dr. Eliot Soren Vance, and I’ve spent years writing about how federal benefit programs intersect with chronic disease. The question I get most often right now isn’t about Social Security payment dates. It’s this: “Does Medicare cover Ozempic for weight loss?” The answer, until very recently, was a firm no. That is changing — but not the way most people think.

The Old Belief: Medicare Simply Does Not Cover Weight-Loss Drugs

For decades, federal law blocked Medicare Part D from paying for drugs prescribed specifically to treat obesity. The logic — outdated as it sounds — treated obesity as a lifestyle issue rather than a chronic disease. That meant Wegovy (semaglutide 2.4 mg), approved by the FDA in 2021 specifically for weight management, was categorically excluded. Beneficiaries who wanted it paid the full retail price: roughly $1,349 per month, depending on pharmacy and dose.

Ozempic (semaglutide 1 mg and 2 mg) existed in a gray zone. It is FDA-approved for type 2 diabetes, not weight loss. Medicare Part D plans were already covering it for diabetic beneficiaries at negotiated rates — sometimes as low as $35 per month under insulin cost-sharing rules that later expanded. But if you used Ozempic off-label for weight loss without a diabetes diagnosis, coverage was never guaranteed.

Rybelsus — the oral form of semaglutide — sat in the same category. Approved for type 2 diabetes management, covered for that purpose, but not for weight reduction alone.

The Surprising Truth: Two Policy Tracks Running Simultaneously

Here is what trips people up. There are two entirely different federal actions happening at the same time, and they are not the same thing.

Track 1 — The Coverage Rule Change (July 2026): CMS proposed to reinterpret the existing statute to permit Medicare Part D coverage of anti-obesity medications for the treatment of obesity when such drugs are prescribed as such. This is a regulatory interpretation shift. It does not automatically mean every Part D plan will cover Wegovy on July 1, 2026. Plans will decide individually whether to add these drugs to their formularies. Coverage rules — including prior authorization, step therapy, and quantity limits — still apply in full.

Track 2 — Drug Price Negotiation (2027): Ozempic, Rybelsus, and Wegovy are selected drugs for the initial price applicability year 2027 of the Medicare Drug Price Negotiation Program. This means the government-negotiated price for these medications — whatever CMS and Novo Nordisk agree to — won’t reach your pharmacy counter until January 2027 at the earliest.

Think of it this way: July 2026 opens the door. January 2027 lowers the price behind that door. You need both to walk in comfortably.

What the New Rules Actually Say — And What They Don’t

Medicare drug coverage, also known as Medicare Part D, helps pay for the brand-name and generic drugs you need. It is offered to everyone with Medicare through private insurers. That structure matters here. CMS sets the rules; private plans execute them. The federal coverage change for obesity drugs means plans may cover these medications — not that they must.

This distinction cost one of my readers — a 68-year-old retiree in Phoenix — roughly $1,927 in a single month. That is about what a one-bedroom apartment runs in Phoenix right now. She assumed “Medicare covers it now” based on news headlines, didn’t check her plan’s formulary, and received a bill for the full amount at the pharmacy counter. Always verify your specific plan.

Medicare drug plans may have rules for how they cover drugs. These rules can include prior authorization, step therapy, and quantity limits. For GLP-1 obesity drugs specifically, expect:

• Prior authorization — your doctor must document a BMI of 30 or higher (or 27+ with a weight-related condition).
• Step therapy — some plans may require documented failure of a lower-cost intervention first.
• Quantity limits — most plans cap monthly dispensing to one pen or one 28-day supply at a time.

What This Changes for Medicare Beneficiaries Right Now

The practical impact is significant but conditional. Here is what I tell readers clearly: Medicare is making GLP-1s available at a reduced cost starting July 2026 — if you want the medications before that, you are paying out of pocket. That out-of-pocket cost averages $936 to $1,349 per month for Wegovy at standard pharmacy prices without a manufacturer coupon.

For context: the average Social Security retirement benefit in

How the July 2026 Coverage Window Actually Works

I want to be precise about the mechanics. Starting July 1, 2026, Medicare Part D plans that opt in to the new obesity-treatment benefit may cover FDA-approved weight-loss drugs like Wegovy. Coverage is not automatic. Your current Part D plan must adopt the benefit, and most plan formulary decisions for mid-year additions depend on CMS guidance released in January 2026.

Three conditions must be met before you see a single dollar of coverage:

1. Your Part D or MA-PD plan adds a qualifying GLP-1 obesity drug to its formulary.
2. Your prescribing physician documents a qualifying obesity diagnosis — typically a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity.
3. You meet any prior authorization criteria your specific plan imposes, which CMS permits.

If all three align, your cost-sharing under standard Part D in 2026 would be subject to the new $2,000 out-of-pocket cap established by the Inflation Reduction Act. After you hit $2,000 in annual drug spending, you pay $0 for the rest of the calendar year. For a drug costing over $1,000 per month, that cap changes everything.

Ozempic Is a Different Story — And Most People Get This Wrong

I receive more questions about Ozempic than any other drug in this category. The confusion is understandable. Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) is FDA-approved only for type 2 diabetes, not obesity. Medicare Part D has covered Ozempic for diabetes since its approval. That has not changed.

What this means practically:

• If you have type 2 diabetes and your doctor prescribes Ozempic, your Part D plan likely covers it now — subject to formulary and prior auth.
• If you want Ozempic only for weight loss, Medicare will not cover it under the new obesity benefit. The FDA label does not support that indication.
• Wegovy (semaglutide 2.4 mg) is the same molecule at a higher dose — but it carries the obesity FDA approval that Ozempic lacks.

The average Medicare beneficiary’s Ozempic cost under Part D in 2025 was approximately $547 per month after coverage before reaching the catastrophic threshold, according to KFF Medicare drug spending analysis. With the new $2,000 cap in 2026, many enrollees with diabetes will exhaust that cap by late spring.

Mounjaro and Zepbound: The Tirzepatide Question

Tirzepatide complicates the picture even further. Eli Lilly markets the same molecule under two brand names:

I find this dual-branding situation ethically thorny to explain. A patient with both obesity and type 2 diabetes may get Mounjaro covered today. A patient with obesity alone must wait until July 2026 — and only if their plan participates. Same drug. Very different access.

Low-Income Subsidy (Extra Help) and GLP-1 Costs

If you receive the Part D Low-Income Subsidy (LIS), also called Extra Help, the calculus shifts. In 2026, full LIS beneficiaries pay no more than $4.50 for generic drugs and $11.20 for brand-name drugs per fill under the standard copay schedule, per SSA.gov Extra Help program details.

However, a brand-name GLP-1 weight-loss drug must first appear on your plan’s formulary to trigger those LIS copays. If your plan doesn’t list Wegovy or Zepbound after July 1, 2026, even $11.20 copays won’t help you. This is where plan selection during the Annual Enrollment Period (October 15–December 7) becomes critical for 2027 coverage.

An estimated 12.9 million Medicare Part D enrollees receive full or partial LIS, according to KFF’s 2026 Part D analysis. For these enrollees, formulary inclusion is the determining factor — not cost-sharing math.

Steps I Recommend Taking Before July 2026

I am not a financial advisor, and nothing here is personal medical advice. But I can outline the concrete informational steps that put you in the best position:

The Behavioral and Mental Health Dimension

I cover mental health and behavioral health alongside pharmacy policy for a reason. GLP-1 drugs do not operate in a vacuum. The FDA issued a communication in January 2024 acknowledging reports of suicidal ideation and depression in some GLP-1 users, prompting an ongoing safety review. As of April 2026, no black-box warning has been added, but prescribers are advised to monitor patients with a history of depression, anxiety, or eating disorders closely.

For Medicare beneficiaries — a population with higher baseline rates of depression than the general adult population — this is not a footnote. It is a clinical priority. If you or a family member is starting a GLP-1 drug, ask your prescriber explicitly about psychiatric monitoring. The drug may be covered. The monitoring visit needs to be scheduled, too.

My Assessment: What 2026 Actually Delivers

I have tracked federal drug coverage policy for years. The July 2026 obesity drug expansion is meaningful — but it is a floor, not a ceiling. Access will be uneven. Formulary participation will vary by plan. Prior authorization hurdles will filter out some qualifying patients in the short term.

What I believe is undeniably true: a Medicare beneficiary who qualifies medically, selects a participating plan, and

Frequently Asked Questions